Altre lingue Palisade Bio, Inc.

Azioni

SNCA

US6963894026

Tempo reale stimato Cboe BZX Altri mercati azionari 15:30:07 08/07/2024			Variaz. 5gg	Var. 1 gen.
4,385 ^USD	-2,34%		-0,22%	-49,27%

21/06	Palisade Bio fornisce un aggiornamento sull'avanzamento della sua collaborazione strategica con Strand Life Sciences	CI
11/06	Palisade Bio annuncia l'avviso di ammissione per il brevetto canadese che copre il prodotto principale candidato, PALI-2108	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Palisade Bio to Participate in the Virtual Investor Closing Bell Series	24/06
Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences	21/06
Palisade Bio Provides Update on Advancement of Its Strategic Collaboration with Strand Life Sciences	21/06
Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108	11/06
Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108	11/06
Palisade Bio to Present at the Virtual Investor Pitch Conference	10/06
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models	21/05
Palisade Bio, Inc. Announces Presentation of Positive Preclinical Data from PALI-2108	21/05
Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update	14/05
Palisade Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Palisade Bio, Inc. announced that it has received $3.999943 million in funding	10/05
Palisade Bio Appoints Margery Fischbein to its Board of Directors	07/05
Palisade Bio, Inc. Appoints Margery Fischbein to Its Board of Directors	07/05
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules	02/05
Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	01/05
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)	01/05
Palisade Bio?s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide	01/05
Palisade Bio, Inc. announced that it expects to receive $3.999996 million in funding	01/05
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach	24/04
Palisade Bio Collaborating With Strand Life Sciences on Ulcerative Colitis Therapy	23/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Palisade Bio, Inc.

Azioni

SNCA

US6963894026

Altre lingue

Filtri